Generalizability and treatment with sodium-glucose co-trasporter-2 inhibitors (SGLT2i) among patients with type 2 diabetes: an assessment using an Italian primary care database.
Antidiabetic drug
Database research
Pharmaco-epidemiology
Primary care
SGLT2 inhibitors
Journal
Acta diabetologica
ISSN: 1432-5233
Titre abrégé: Acta Diabetol
Pays: Germany
ID NLM: 9200299
Informations de publication
Date de publication:
29 Aug 2024
29 Aug 2024
Historique:
received:
29
04
2024
accepted:
04
08
2024
medline:
31
8
2024
pubmed:
31
8
2024
entrez:
29
8
2024
Statut:
aheadofprint
Résumé
This study aimed to assess the proportions of type 2 diabetes (T2D) subjects meeting cardiovascular outcome trials (CVOTs) criteria for sodium-glucose cotransporter-2 inhibitors (SGLT-2i) and estimate SGLT2i utilization, along with associated demographic and clinical characteristics, in a primary care setting. T2D patients in Italy were selected between January 1, 2021, and December 31, 2022, from The Health Improvement Network (THIN Out of 17,102 T2D patients, 8,828 met eligibility criteria for at least one CVOT. DECLARE-TIMI 58 exhibited the highest representativeness (51.1%), compared to CANVAS (21.1%), EMPA-REG OUTCOME (5.5%), and VERTIS-CV (4.9%) trials. Eligible CVOTs patients were older (74.6 vs. 68.3 years), with a longer disease duration (10.2 vs. 9.7 years), and higher established cardiovascular disease (CVD) prevalence (36.0 vs. 27.3%) compared to SGLT2i users. Less than 10% of eligible T2D patients received SGLT2i. Males (OR: 1.43; 95%CI: 1.24-1.66) were more likely to be prescribed SGLT2i than other antidiabetic drugs, while the elderly (80 + vs. 40-64 years, OR: 0.17; 95% CI: 0.14-0.22) were less likely. Eligible T2D patients with CVD reported an increased likelihood of receiving SGLT2is compared to other antidiabetics. This study highlights significant variability in the proportion of T2D subjects meeting SGLT2i CVOT inclusion criteria, with DECLARE-TIMI-58 being the most represented. Low SGLT2i prescription rates in the Italian primary care setting, along with substantial demographic and clinical differences between SGLT-2i users and T2D eligible patients, emphasize the need for targeted interventions to optimize the use of these medications in primary care settings.
Identifiants
pubmed: 39207490
doi: 10.1007/s00592-024-02359-1
pii: 10.1007/s00592-024-02359-1
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
GBD 2021 Diabetes Collaborators (2023) Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the global burden of Disease Study 2021. Lancet 402:203–234. https://doi.org/10.1016/S0140-6736(23)01301-6
doi: 10.1016/S0140-6736(23)01301-6
Cosentino F, Grant PJ, Aboyans V et al (2020) 2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J 41:255–323. https://doi.org/10.1093/eurheartj/ehz486
doi: 10.1093/eurheartj/ehz486
pubmed: 31497854
American Diabetes Association (2018) Lifestyle Management: standards of Medical Care in Diabetes-2018. Diabetes Care 41:4. https://doi.org/10.2337/dc18-S004
doi: 10.2337/dc18-S004
van Baar MJB, van Ruiten CC, Muskiet MHA et al (2018) SGLT2 inhibitors in combination therapy: from mechanisms to clinical considerations in type 2 diabetes management. Diabetes Care 41:1543–1556. https://doi.org/10.2337/dc18-0588
doi: 10.2337/dc18-0588
pubmed: 30030256
Salvatore T, Galiero R, Caturano A et al (2022) An overview of the Cardiorenal Protective mechanisms of SGLT2 inhibitors. Int J Mol Sci 23:3651. https://doi.org/10.3390/ijms23073651
doi: 10.3390/ijms23073651
pubmed: 35409011
pmcid: 8998569
Cannon CP, McGuire DK, Pratley R et al (2018) Design and baseline characteristics of the eValuation of ERTugliflozin effIcacy and safety CardioVascular outcomes trial (VERTIS-CV). Am Heart J 206:11–23. https://doi.org/10.1016/j.ahj.2018.08.016
doi: 10.1016/j.ahj.2018.08.016
pubmed: 30290289
Neal B, Perkovic V, Mahaffey KW et al (2017) Canagliflozin and Cardiovascular and renal events in type 2 diabetes. N Engl J Med 377:644–657. https://doi.org/10.1056/NEJMoa1611925
doi: 10.1056/NEJMoa1611925
pubmed: 28605608
Zinman B, Wanner C, Lachin JM et al (2015) Empagliflozin, Cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373:2117–2128. https://doi.org/10.1056/NEJMoa1504720
doi: 10.1056/NEJMoa1504720
pubmed: 26378978
Wiviott SD, Raz I, Bonaca MP et al (2019) Dapagliflozin and Cardiovascular outcomes in type 2 diabetes. N Engl J Med 380:347–357. https://doi.org/10.1056/NEJMoa1812389
doi: 10.1056/NEJMoa1812389
pubmed: 30415602
Van Spall HGC, Toren A, Kiss A, Fowler RA (2007) Eligibility criteria of randomized controlled trials published in high-impact general medical journals: a systematic sampling review. JAMA 297:1233–1240. https://doi.org/10.1001/jama.297.11.1233
doi: 10.1001/jama.297.11.1233
pubmed: 17374817
He J, Morales DR, Guthrie B (2020) Exclusion rates in randomized controlled trials of treatments for physical conditions: a systematic review. Trials 21:228. https://doi.org/10.1186/s13063-020-4139-0
doi: 10.1186/s13063-020-4139-0
pubmed: 32102686
pmcid: 7045589
Davies MJ, D’Alessio DA, Fradkin J et al (2018) Management of hyperglycemia in type 2 diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 41:2669–2701. https://doi.org/10.2337/dci18-0033
doi: 10.2337/dci18-0033
pubmed: 30291106
pmcid: 6245208
Birkeland KI, Bodegard J, Norhammar A et al (2019) How representative of a general type 2 diabetes population are patients included in cardiovascular outcome trials with SGLT2 inhibitors? A large European observational study. Diabetes Obes Metab 21:968–974. https://doi.org/10.1111/dom.13612
doi: 10.1111/dom.13612
pubmed: 30537226
pmcid: 6590461
Canivell S, Mata-Cases M, Vlacho B et al (2019) How many patients with type 2 diabetes meet the inclusion criteria of the Cardiovascular outcome trials with SGLT2 inhibitors? Estimations from a Population Database in a Mediterranean Area. J Diabetes Res 2019(2018374). https://doi.org/10.1155/2019/2018374
Hinton W, Feher M, Munro N et al (2020) Sodium-glucose co-transporter-2 inhibitor cardiovascular outcome trials and generalizability to English primary care. Diabet Med 37:1499–1508. https://doi.org/10.1111/dme.14290
doi: 10.1111/dme.14290
pubmed: 32128875
pmcid: 7497070
Wittbrodt E, Chamberlain D, Arnold SV et al (2019) Eligibility of patients with type 2 diabetes for sodium-glucose co-transporter-2 inhibitor cardiovascular outcomes trials: an assessment using the Diabetes Collaborative Registry. Diabetes Obes Metab 21:1985–1989. https://doi.org/10.1111/dom.13738
doi: 10.1111/dom.13738
pubmed: 30968543
pmcid: 6767768
Shao S-C, Lin Y-H, Chang K-C et al (2019) Sodium glucose co-transporter 2 inhibitors and cardiovascular event protections: how applicable are clinical trials and observational studies to real-world patients? BMJ Open Diabetes Res Care 7:e000742. https://doi.org/10.1136/bmjdrc-2019-000742
doi: 10.1136/bmjdrc-2019-000742
pubmed: 32043472
pmcid: 6954814
Nicolucci A, Candido R, Cucinotta D et al (2019) Generalizability of Cardiovascular Safety trials on SGLT2 inhibitors to the Real World: implications for clinical practice. Adv Ther 36:2895–2909. https://doi.org/10.1007/s12325-019-01043-z
doi: 10.1007/s12325-019-01043-z
pubmed: 31410779
Italian Medicine Agency (AIFA) Nota 100. URL: https://www.aifa.gov.it/en/nota-100
Antonazzo IC, Rozza D, Conti S et al (2023) Treatment patterns in essential tremor: real-world evidence from a United Kingdom and France primary care database. Eur J Neurol. https://doi.org/10.1111/ene.16064
doi: 10.1111/ene.16064
pubmed: 37738526
pmcid: 11235796
Blak BT, Thompson M, Dattani H, Bourke A (2011) Generalisability of the Health Improvement Network (THIN) database: demographics, chronic disease prevalence and mortality rates. Inf Prim Care 19:251–255. https://doi.org/10.14236/jhi.v19i4.820
doi: 10.14236/jhi.v19i4.820
Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373–383. https://doi.org/10.1016/0021-9681(87)90171-8
doi: 10.1016/0021-9681(87)90171-8
pubmed: 3558716
Charlson ME, Charlson RE, Peterson JC et al (2008) The Charlson comorbidity index is adapted to predict costs of chronic disease in primary care patients. J Clin Epidemiol 61:1234–1240. https://doi.org/10.1016/j.jclinepi.2008.01.006
doi: 10.1016/j.jclinepi.2008.01.006
pubmed: 18619805
van der Aart AB, de Boer RA, Heerspink HJL (2022) Kidney and heart failure outcomes associated with SGLT2 inhibitor use. Nat Rev Nephrol 18:294–306. https://doi.org/10.1038/s41581-022-00535-6
doi: 10.1038/s41581-022-00535-6
Yau K, Dharia A, Alrowiyti I, Cherney DZI (2022) Prescribing SGLT2 inhibitors in patients with CKD: expanding indications and practical considerations. Kidney Int Rep 7:1463–1476. https://doi.org/10.1016/j.ekir.2022.04.094
doi: 10.1016/j.ekir.2022.04.094
pubmed: 35812300
pmcid: 9263228
Morieri ML, Avogaro A, Fadini GP (2020) Long-acting Injectable GLP-1 receptor agonists for the treatment of adults with type 2 diabetes: perspectives from clinical practice. Diabetes Metab Syndr Obes 13:4221–4234. https://doi.org/10.2147/DMSO.S216054
doi: 10.2147/DMSO.S216054
pubmed: 33204129
pmcid: 7665457
Lewis JD, Schinnar R, Bilker WB et al (2007) Validation studies of the health improvement network (THIN) database for pharmacoepidemiology research. Pharmacoepidemiol Drug Saf 16:393–401. https://doi.org/10.1002/pds.1335
doi: 10.1002/pds.1335
pubmed: 17066486